India’s Drug Industry Worries Whether New Pricing Policy Robust Enough
This article was originally published in PharmAsia News
Some of the largest brands are faced with losing their sheen as debate heats up in the drug industry over whether the new Indian drug pricing system is robust enough to deliver needed reform.
You may also be interested in...
Size Is Rewarded When Fostering Brand In India, But Pricing Has To Be Right: Elsevier Business Intelligence Webinar
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.